Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Regeneron Pharmaceuticals (NQ: REGN )

747.09 +2.59 (+0.35%)
Streaming Delayed Price Updated: 12:19 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >
If You Invested $1000 In This Stock 20 Years Ago, You Would Have $130 Thousand Today
Via Benzinga
Biotech Bull Market: 3 Ways To Play It
Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally. 
Via Talk Markets
Topics Economy
Exposures Interest Rates
Alphabet Turns Twenty
Twenty years ago to the day, the company running the world's largest search engine went public. On August 19th, 2004, Alphabet shares IPO'd at a split-adjusted price of $2.13. 
Via Talk Markets
7 Stocks That Usually Benefit From a Recession
These seven stocks have historically shown resilience during economic downturns and could potentially benefit from a recession. 
Via InvestorPlace
Insights Into Regeneron Pharmaceuticals's Performance Versus Peers In Biotechnology Sector
Via Benzinga
$100 Invested In This Stock 20 Years Ago Would Be Worth $15,000 Today
Via Benzinga
Analyst Ratings For Regeneron Pharmaceuticals
Via Benzinga
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
Via Benzinga
Apple, Amazon, Microsoft, Meta Lead The Charge As Investors Bank On Tech Cheer For Rally's Reacceleration: Week Ahead In Earnings
The unfolding week's market trajectory depends on earnings from bellwether tech stocks and what the Fed has to say following its July meeting. 
Via Benzinga
Topics Economy
Exposures Interest Rates
3 Biotech Stocks Poised for a Comeback After Last Week’s Market Meltdown
Investors should closely watch these three biotech stocks as their strong prospects are likely to help the rebound from market volatility. 
Via InvestorPlace
3 Biotech Stocks With Promising Drug Pipelines: August 2024
The biotech stocks with promising pipelines could see shares soar if drugs in late-stage trials get FDA approval. 
Via InvestorPlace
Exposures Product Safety
Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
3 Healthcare Stocks Positioned for Possible Market Outperformance
While healthcare stocks might not be as shiny as they were in the pandemic era, these three could outperform the broader market. 
Via InvestorPlace
Is Regeneron Pharmaceuticals Due for a Stock Split?
Would a stock split help lead Regeneron Pharmaceuticals shares higher? 
Via The Motley Fool
$100 Invested In This Stock 15 Years Ago Would Be Worth $5,100 Today
Via Benzinga
Peering Into Regeneron Pharmaceuticals's Recent Short Interest
Via Benzinga
Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology
Via Benzinga
Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review
Apple and Meta had strong results, while AI spending remains robust. 
Via Investor's Business Daily
Topics Artificial Intelligence
Exposures Artificial Intelligence
Regeneron Pharmaceuticals' Q2 Earnings Exceed Estimates, Driven By Its Top-Selling Eczema And Eye Drugs
Regeneron Pharmaceuticals Q2 results: adjusted EPS of $11.56 (up 13%), revenue of $3.55 billion (up 12%). Key drivers: Eylea HD, Dupixent, and Libtayo. Notable: 18% decline in Eylea US sales; 42%... 
Via Benzinga
Regeneron Stock Climbs After Strong Second-Quarter Performance
A strong second-quarter performance lifted the already extended shares of the New York-based drug maker Regeneron. 
Via Investor's Business Daily
Regeneron Reports Second Quarter 2024 Financial and Operating Results
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
US Stocks Tumble On Economic, Geopolitical Concerns; Small Caps, Chipmakers Sink; Meta Rallies: What's Driving Markets Thursday?
Markets experienced a sharp downturn, driven by heightened geopolitical tensions and economic uncertainties that negatively impacted investor risk sentiment, just a day after the Federal Open Market... 
Via Benzinga
Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Wall Street Looks To Ride On Earnings Cheer As Meta Q2 Impresses Investors: Analyst Says Economic Data, Stock Performances Suggest Republican Win In November
After Wednesday’s tech-led rebound amid the Federal Reserve’s rate decision, the stock market could be in for further gains. The major index futures point to a higher opening, although suggesting a... 
Via Benzinga
Bull Market Buys: 2 Growth Stocks to Own for the Long Run
These companies are no strangers to beating the market. 
Via The Motley Fool
Sanofi Raises 2024 Profit Outlook On Strong Q2 Earnings, Blockbuster Drug Dupixent Sees Strong Demand
Sanofi reports a 7.8% YoY sales increase in Q2, with sales reaching $11.57 billion, beating consensus. Key highlights include a 29.2% rise in Dupixent sales and a stable 2024 business EPS forecast. 
Via Benzinga
MAIA Biotechnology's Lung Cancer Drug Shows Promising Long-Term Benefits In Advanced Patients
MAIA Biotechnology's Phase 2 THIO-101 trial shows promising updates for THIO with Regeneron's cemiplimab in advanced NSCLC patients. Results include a 38% ORR, 85% DCR, and lower toxicity, with six... 
Via Benzinga
Johnson & Johnson Prioritizes Sustainable Growth in M&A Amid Sector Diversification, Says Analyst
Johnson & Johnson reports Q2 EPS of $2.82, up 10.2% YoY, beating expectations. Analysts foresee strong MedTech markets ahead, with ongoing M&A strategy emphasizing sustainable growth. 
Via Benzinga
3 Standout Stocks to Buy for the Next Bull Market
These standout stocks to buy for a bull market offer promising potential for significant gains as market conditions continue to strengthen. 
Via InvestorPlace
Stocks to Buy: 7 Founder-Led Companies Set to Outperform
These founder-led companies are at the forefront of industry innovation, and historical trends indicate that they will likely outperform. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.